PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.

Trial Details

NCT ID
NCT04683315
Phase
PHASE2
Sponsor
Medical College of Wisconsin
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • mFOLFIRINOX Treatment Regimen
  • Gemcitabine/Nab-paclitaxel Treatment Regimen
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Milwaukee, Wisconsin, United States|43.0389,-87.90647

Key Eligibility Criteria

  • Have suspicion of pancreas adenocarcinoma and plan for endoscopic biopsy.
  • Plan for endoscopic biopsy or agreeable to an additional EUS/FNA for research purposes, otherwise plan to obtain archival tissue for PurlST testing.
  • Inclusion Criteria (for Treatment)
  • Be 18 years of age or older.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →